Phase 1/2Active, not recruiting
ALSENLITE: Senolytics for Alzheimer's Disease
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
- Sponsor
- Mayo Clinic (Academic or other)
- Enrolment
- 20 planned
- Conditions
- Mild Cognitive Impairment; Alzheimer Disease
- Interventions
- Dasatinib; Quercetin
- Ages
- adults, older adults
- Registry
- NCT04785300
From the registry
This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.
Primary outcomes
- Safety and Tolerability